Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Published:2013-01 Issue:9860 Volume:381 Page:29-39
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Teerlink John R,Cotter Gad,Davison Beth A,Felker G Michael,Filippatos Gerasimos,Greenberg Barry H,Ponikowski Piotr,Unemori Elaine,Voors Adriaan A,Adams Kirkwood F,Dorobantu Maria I,Grinfeld Liliana R,Jondeau Guillaume,Marmor Alon,Masip Josep,Pang Peter S,Werdan Karl,Teichman Sam L,Trapani Angelo,Bush Christopher A,Saini Rajnish,Schumacher Christoph,Severin Thomas M,Metra Marco

Publisher

Elsevier BV

Subject

General Medicine

Reference43 articles.

1. Heart disease and stroke statistics—2012 update: a report from the American Heart Association;Roger;Circulation,2012

2. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot);Maggioni;Eur J Heart Fail,2010

3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

4. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure;Damasceno;Arch Intern Med,2012

5. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008;Chen;JAMA,2011

Cited by 797 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes;Biochemical Pharmacology;2024-11

2. Prognostic association of circulating relaxin-2 in acute heart failure;International Journal of Cardiology;2024-10

3. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology;Biochemical Pharmacology;2024-09

4. Rule-based natural language processing to examine variation in worsening heart failure hospitalizations by age, sex, race and ethnicity, and left ventricular ejection fraction;American Heart Journal;2024-09

5. Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study;Journal of the American Heart Association;2024-08-06